Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

Original reporting
Published Oct 30, 2026, 3:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second — source image
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

The earnings call provides fresh guidance and margin details that could move PHAT and affect biotech sentiment.

02

Market read

Earnings and guidance could drive PHAT's stock and influence the broader biotech sector.

03

What to watch

Potential upside from upcoming Phase 2 data and business development opportunities.

Relevance 7/10Novelty 8/10Timing: today

Background

Phathom Pharmaceuticals held its Q3 2026 earnings call, discussing results and outlook.

Company-level read

Ticker impact

$PHATBullishMedium confidence
Context

Q3 earnings reveal a one-time manufacturing charge causing margin decline and Q4 guidance set at the lower end of the 55%-59% range.

Expected impact

likely modest pressure as market prices in the margin decline and guidance uncertainty

Evidence & confidence

One-time charge hurts gross margin, while guidance remains conservative, suggesting limited upside potential.

Market effects

Biotech earnings may influence sentiment across small-cap pharma stocks.

Primarily impacts U.S. biotech investors.

Limited to niche biotech sector, no broad market effect.

Counterpoint

Margin decline could be temporary; guidance may be upgraded if pipeline progresses.

Key entities

  • Phathom Pharmaceuticals Inc.

    Biopharmaceutical company reporting Q3 results.

  • Steve Basta

    CEO of Phathom Pharmaceuticals.

  • Sanjeev Narula

    CFO of Phathom Pharmaceuticals.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.

$PHATMedAI 8/10

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G